Skip to search formSkip to main contentSkip to account menu

seribantumab

A fully human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

5 relations
MM-121NCIt Antineoplastic Agent Terminologyantigen binding

Broader (1)

Monoclonal Antibodies

Narrower (1)

SAR256212

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
9036 Background: Seribantumab (MM-121) is a human monoclonal IgG2 antibody that blocks the HRG domain of HER3. Preclinical data… 
2018
2018
Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Human epidermal growth factor receptor type 3 (HER3) is recognized to be involved in resistance to HER-targeting therapies. A… 
2018
2018
Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive…
Background: The receptor tyrosine kinase, HER3 and its ligand, heregulin (HRG), have been implicated in the initiation and… 
Review
2017
Review
2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (EGFR/ErbB1), human EGFR 2… 
2017
2017
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
SummaryBackground HER3/EGFR heterodimers have been implicated as a mode of resistance to EGFR-directed therapies. Methods This… 
2017
2017
Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup…
Heregulin (HRG) is the cognate ligand of the human epidermal growth factor receptor 3 (ErbB3) and has been identified as a potent… 
2017
2017
Affibody molecules targeting HER3 for cancer therapy
The development of targeted therapy has contributed tremendously to the treatment of patients with cancer. The use of highly… 
2017
2017
Evaluating the therapeutic potential of a dimeric HER 3-binding affibody construct in comparison with a monoclonal antibody , seribantumab MANUSCRIPT
The use of monoclonal antibodies or their derivatives to improve survival of patients with disseminated cancer is today… 
2016
2016
A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic…
TPS9110Background: The role of the HER3 receptor and its ligand heregulin (HRG) in the progression of multiple cancers has been… 
2015
2015
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model
Heregulin-driven ERBB3 signaling has been implicated as a mechanism of resistance to cytotoxic and antiendocrine therapies in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)